Analysis of Induced Pluripotent Stem Cell (iPSC) market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
The global induced pluripotent stem cell (iPSC) market stands at a valuation of US$ 1.8 Bn in 2022, and is projected to climb to US$ 2.3 Bn by the end of 2026.
Over the 2022 to 2026 period, worldwide demand for induced pluripotent stem cells is anticipated to rise rapidly at a CAGR of 6.6%. The China iPSC market is expected to surge ahead at a CAGR of 8.5% over the same time frame.
Induced Pluripotent Stem Cell Market Size (2022)
US$ 1.8 Bn
Projected Year Value (2026F)
US$ 2.3 Bn
Global Market Growth Rate (2022-2026)
United States Market Worth (2022)
US$ 820.4 Mn
Key Companies Profiled
Increasing spending on research and development activities in the healthcare industry is projected to drive the popularity of human iPS cell lines in applications such as precision and personalized medicine.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Investments in healthcare research and development have substantially increased over the past few years, and this trend is expected to prominently influence induced pluripotent stem cell demand through 2026. Increasing scope of application of human iPSC cell lines in precision medicine and rising focus on therapeutic applications of stem cells are expected to be major factors driving induced pluripotent stem cell market growth.
Rising government spending and increasing awareness about stem cell research across organizations are also predicted to positively influence demand for induced pluripotent stem cells. Rising prevalence of chronic diseases and the use of stem cells in their treatment will also favor market growth potential.
However, high costs associated with stem cell research and the longer time taken to develop and deploy induced pluripotent stem cells are expected to have a hindering effect on the global iPSC market. Moreover, ethical concerns regarding stem cell research and therapies are also expected to have a constraining effect on global induced pluripotent stem cell demand.
Nevertheless, the global market for induced pluripotent stem cell is expected to rise at a CAGR of 6.6% from 2022 to 2026.
“North America Accounts for Major Market Share Owing to High Research Activity”
The North America induced pluripotent stem cells market is projected to exhibit highly lucrative opportunities for induced pluripotent stem cell suppliers owing to high research and development activity in this region.
Increasing investments from the government and the presence of developed healthcare infrastructure are also expected to favor the market potential through 2026.
The Canada induced pluripotent stem cell market is anticipated to expand at a CAGR of 6.8% from 2022 to 2026.
Growing contract research organizations in Europe are expected to drive the market for induced pluripotent stem cells across the forecast period. Rising demand for clinical research owing to the increasing establishment of large-scale and small biotechnology companies is anticipated to favor iPSC market growth in Europe. Demand for induced pluripotent stem cells in Germany is projected to rise at a CAGR of 6.5% across the forecast period.
Increasing research and development projects in regions of East Asia, South Asia, and Oceania regions are expected to boost induced pluripotent stem cell demand through the forecast period of 2022 to 2026.
China, Japan, Singapore, and Australia are expected to emerge as the most lucrative markets for induced pluripotent stem cells in these regions. The Japan induced pluripotent stem cell industry is predicted to rise at a CAGR of 5.5% over the years to come.
“Increasing Support from Government to Aid Induced Pluripotent Stem Cell Vendors”
The U.S. is anticipated to emerge as a highly rewarding market for induced pluripotent stem cell suppliers over the forecast period owing to high research and development activity in the healthcare sector.
Stem cell therapy providers are expected to target the U.S. to generate high revenue as the government in the nation is providing investments to advance research in stem cell applications.
Embryonic stem cells, neural stem cells, umbilical cord stem cells, etc. are anticipated to see high demand in the U.S. owing to the rising popularity of stem cell therapies.
At present, the U.S. iPSC market accounts for a net value of US$ 820.4 Mn.
“Increasing Scope of Application of Cardiac Cells to Be Witnessed”
Instances of cardiovascular diseases have risen substantially over the past few years and are expected to follow a similar trend over the coming years.
Demand for human-induced pluripotent stem cell cardiomyocytes is expected to increase as their scope of application in cardiotoxicity testing and other processes rises in the medical industry.
Adult stem cells are mostly used for cardiac applications.
“Increasing Incidence of Neural Disorders & Rising Use of Stem Cell Therapy Driving Demand”
The world has witnessed an increase in the incidence of neurological disorders and the demand for novel treatments for the same is also high. Stem cell therapies have proven to be helpful in the regeneration of new cells which could provide better treatment opportunities and hence neural stem cells are anticipated to see high demand through 2026.
Increasing demand for use of neural stem cells in the treatment of disorders such as Alzheimer’s and Parkinson’s is expected to be a prominent trend over the coming years.
The sudden emergence of COVID-19 in 2020 led to major changes in global healthcare trends and changed the way markets performed in these unprecedented times. As infections plagued the world, most nations imposed lockdowns to curb the spread of infections and contain the pandemic situation. These lockdowns led to hampered research and development activity, and hence, had a negative impact on the global iPSC marketplace.
However, the use of induced pluripotent stem cells for the treatment of coronavirus infections was also being explored during the pandemic, which kept the market afloat to a certain extent in these adverse times.
The iPSC market is expected to perform well in the post-pandemic era as research activities resume with the retraction of lockdown restrictions. Demand for induced pluripotent stem cells is expected to evolve at a high pace over the next few years.
Induced pluripotent stem cell suppliers are increasing their investments in research and development to advance their offerings in stem cell therapies which are gaining popularity for the treatment of multiple chronic diseases.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesBuy Now
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
- Related Reports -
The global induced pluripotent stem cell market stands a valuation of US$ 1.8 Bn in 2022.
By 2026, the induced pluripotent stem cell market is anticipated to reach US$ 2.3 Bn.
The global market for induced pluripotent stem cells is expected to surge at a CAGR 6.6% from 2022 to 2026.
From 2022 to 2026, demand for induced pluripotent stem cells in China is projected to rise at a CAGR of 8.5%.
Currently, the U.S. induced pluripotent stem cell market accounts for a net value of US$ 820.4 Mn.
The Japan induced pluripotent stem cell market is projected to progress at a steady CAGR of 5.5% from 2022 to 2026.
Need An Exclusive Report For Your Unique Requirement?